The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

It took many years for investigators to find an effective treatment that could extend survival beyond androgen deprivation therapy for patients with metastatic castration-resistant prostate cancer. The answer was found in the chemotherapy docetaxel in 2004. The next 13 years saw the approval of 8 treatments for the same disease

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.